Avid Bioservices Inc (CDMO)

[north40000]

CP, you said:

"The 4 meaningful players at this moment, BMY, Merck, Roche and AstraZeneca all have an anti PD-1 or anti PD-L1. So with a SAME WEAPON, that by the way has the SAME shortcomings in tremendous side effects and limited responders, it will be something else that will make the difference."

As I noted earlier this afternoon in my GILD-directed post, GILD's CSO noted the same thing sitting through various ASCO presentations....the RRRs were dismal... ~ 20% or so. GILD will seek to improve that situation...the question is how?

Data from those small, short trials you suggest will potentially drive a host of individualized field of use licenses for PPHM. Let's see what happens.